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Abstract
The progressive aggregation of Amyloid-β (Aβ) in the brain is a major trait of Alzheimer's
Disease (AD). Aβ is produced as a result of proteolytic processing of the β-amyloid precur-
sor protein (APP). Processing of APP is mediated by multiple enzymes, resulting in the pro-
duction of distinct peptide products: the non-amyloidogenic peptide sAPPα and the
amyloidogenic peptides sAPPβ, Aβ40, and Aβ42. Using a pathway-based approach, we
analyzed a large-scale siRNA screen that measured the production of different APP proteo-
lytic products. Our analysis identified many of the biological processes/pathways that are
known to regulate APP processing and have been implicated in AD pathogenesis, as well
as revealing novel regulatory mechanisms. Furthermore, we also demonstrate that some of
these processes differentially regulate APP processing, with some mechanisms favouring
production of certain peptide species over others. For example, synaptic transmission hav-
ing a bias towards regulating Aβ40 production over Aβ42 as well as processes involved in
insulin and pancreatic biology having a bias for sAPPβ production over sAPPα. In addition,
some of the pathways identified as regulators of APP processing contain genes (CLU,
BIN1, CR1, PICALM, TREM2, SORL1, MEF2C, DSG2, EPH1A) recently implicated with
AD through genome wide association studies (GWAS) and associated meta-analysis. In ad-
dition, we provide supporting evidence and a deeper mechanistic understanding of the role
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Introduction
Progressive aggregation of a toxic 42 amino-acid peptide species, known as amyloid-beta (Aβ)
42 is a major hallmark of Alzheimer’s disease (AD). Accumulation of Aβ42 oligomers is
thought to cause neuronal injury, synaptic dysfunction, and neuronal death leading to demen-
tia[1,2]. Aβ42 is produced as a result of proteolytic processing of the amyloid precursor protein
(APP), a ~100-KDa type I transmembrane protein that is ubiquitously expressed and localized
to the trans-Golgi network, endocytic compartments, and cell surface. Sequential cleavage of
APP by β- and γ-secretases results in the production of Aβ peptides (Aβ40 and Aβ42) and,
hence, several drug-discovery efforts are aimed at finding either β-secretase (BACE1) or γ-
secretase inhibitors (GSIs)[3,4]. However, the development of small molecules for either of
these targets has proven to be challenging. BACE1 is an aspartyl protease with a large active
site that complicates the identification of suitable brain-penetrant small molecules[3,4]. Con-
versely, several highly potent and cell-permeable GSIs have been identified. However, the de-
velopment of GSIs has been plagued by mechanism-based toxicities. In addition to APP, the γ-
secretase complex has many (>40) other substrates[5], most notably Notch. Proteolytic pro-
cessing of Notch by γ-secretase results in the release of the Notch intracellular signalling do-
main (NICD), a process that is inhibited by treatment with GSIs. Chronic inhibition of Notch
processing is thought to result in gastrointestinal as well as other toxicities, which are dose lim-
iting in the clinic[3,4,6,7]. Therefore, given the challenges with current therapeutic strategies
and the recent identification of protective mutations in APP that lower amyloid levels[8], the
identification of alternative ways of regulating Aβ42 production is needed.
Several observations support the notion that alternative approaches to direct BACE1 and γ-
secretase inhibition are possible. Oxidative stress, transient interactions with the γ-secretase
complex, neuronal activity, cholesterol metabolism, and inflammatory cytokines can directly
modulate γ-secretase activity[9]. Therapeutic strategies exploiting many of these processes
have been proposed, with some progressing through clinical trials[3,7]. However, the underly-
ing mechanisms by which some of these processes affect Aβ levels are still poorly understood
[1,9], complicating the identification and development of novel therapeutic strategies.
Whole-genome siRNA screens provide a powerful means for target identification. By
knocking down a gene with siRNA nucleotide probes, one is able to measure the effect on dif-
ferent biological outcomes for thousands of genes simultaneously, enabling the identification
of pathways and processes that regulate the biology of interest. However, there are many chal-
lenges facing the analysis of siRNA screens. The fact that siRNA probes may not be specific,
due to sequence similarity with other genes, results in off-target activities and thus potentially
contributes to the high rate of false-positive hits and the low level of reproducibility[10,11].
False negatives are likely to occur due to variations in: (1) probe efficacy; (2) protein stability;
and (3) the magnitude of a true biological response, since the position or role of a given gene/
protein in a pathway would allow for only a small, yet significant effect on the biology being
measured[11–14]. Currently, target (hit) selection is generally handled on an individual basis
devoid of any biological context with the main focus on identifying highly active hits defined
either by a rank, such as percent activity, or by the use of a Z-score[11,12]. This type of analysis
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focuses mainly on the extreme values of the distribution representing ~1% of the measured val-
ues whilst ignoring the remainder of the data[12]. This led to the development of methods that
consider the collective effects of siRNA probes, targeting the same gene, in the identification of
likely gene candidates [11,15,16]. Similarly, given that genes belonging to the same pathway/
process will act in concert to exert their effect on a biological outcome and that not all genes in
a given pathway/process will have uniform effects on biological endpoints, we can leverage
pathway or gene set scoring as a complementary approach to the analysis of siRNA screens.
Our assumption is that the aggregate effect of genes in a pathway should not occur merely by
chance and would also take into account small, but real effects to be considered [17–19].
Here we apply a pathway scoring method to a large-scale siRNA screen aimed at identifying
regulators of APP processing. The screen measures the production of APP proteolytic prod-
ucts, the non-amyloidogenic peptide (sAPPα) and the amyloidogenic peptides (sAPPβ, Aβ40,
and Aβ42), as well as cell viability[20]. By applying such a method, we were able to derive, for
the first time, the “regulatory landscape of APP processing”, identifying most pathways/
processes that have been previously implicated in the regulation of APP endoproteolysis, in-
cluding processes that contain key genetic risk factors identified in recent Genome-Wide Asso-
ciation (GWA) studies for AD[21–25], as well as novel regulatory mechanisms. In addition, we
demonstrate how pathway-based analysis can be used to: (1) identify the interplay across dif-
ferent regulatory pathways/processes; (2) understand how production of APP peptides can be
regulated by common or distinct mechanisms; (3) propose mechanistic hypotheses as to how a
diabetes-related pathway can affect APP processing and (4) provide a framework from which
novel amyloid therapeutic strategies could be derived.
Results
Identification of pathways that differentially regulate APP processing and
cell viability
In order to identify the pathways/biological processes that regulate APP processing and viability,
both net and absolute pathway impact (PI) scores were calculated (see Materials & Methods).
Briefly, the PI score represents a normalized aggregate effect of all the genes in a given pathway/
process. Since genes in a given pathway can either increase or decrease the readout in question
by being either “activators” or “inhibitors”, both Net and absolute PI (ABS PI) scores were calcu-
lated. The ABS PI score accounts for the scenario where small Net PI scores are obtained due to
equal, but opposing effects of genes in a given pathway/process and reflects whether a pathway/
process regulates the biological readout independent of the direction of the effect. Net PI and
ABS PI scores for pathway/process sets from several public and commercial databases across all
biological endpoints measured were calculated (6154 sets in total) (S1–S3 Supplementary Infor-
mation). Because the PI score may depend on the size of the pathway/process, we also calculated
the probability of obtaining such a score by chance for each given set size (see Materials &
Methods).
A pathway was considered significant at a P 0.01 for either Net or ABS PI. Table 1 lists
the number of pathways/processes identified as significant for each readout (viability, Aβ40,
Aβ42, sAPPα, and sAPPβ), respectively. In total, 372 pathway/process sets were identified as
significant for at least one of the readouts. Given the central role of Aβ42 in AD pathology, we
will focus most of the Results section on pathways identified for this readout and will discuss,
when relevant, the results for the other readouts (see Table 1 and S4 and S5 Supplementary
Information).
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Table 1. APP processing landscape.




Summary of Key Pathways/Process (Table 1)
Viability 111(90) 3192 1) Activin A signaling, TGF-b receptor signaling pathway (CLU), receptor protein serine/
threonine kinase signaling, senescence, nuclear import, peroxisome transport, IL12 signaling (via
STAT4), Immune response (MHC class II), TCR signaling, Osteopontin-mediated events, VEGF
signaling, PECAM1 interactions, Macropinocytosis, S1P3 pathway, Integrin signaling (via Grb2:
SOS, MAPK; amb2), Blood coagulation, cytoskeleton remodeling, NGF receptor signaling, G-
protein signaling (via Rap1A), EphB receptors in dendritic spines, cytoskeleton remodeling, folic
acid transport, mitochondrion organization 2) proteosomal degradation (ubiquitin dependent) 3)
mRNA metabolism (transcription, translation, splicing), Ribosome, Inﬂuenze viral replication,
glucose homeostasis 4) copper ion transport, aerobic respiration, response to ATP 5) Mismatch
repair, somatic hypermutation of immunoglobulin genes 6) Tyrosine metabolism 7) response to
acetate 8) regulation of angiotensin metabolic process 9) chitin metabolic process
Aβ40 95(67) 2837 1)Axogenesis (SORL1); neuron and neurite development (SORL1); cell-cell junction
maintenance; cell morphogenesis and projection (SORL1); integrin-mediated signaling (via
p130Cas and MAPK); autophagy; PECAM1 interactions (INPP5D); memory; Plug formation 2)
nitric oxide metabolism; granulocyte macrophage colony stimulation; Immunity and defense
(CR1); Natural killer cell mediated immunity, protein destabilization, mRNA metabolism
(transcription) 3)DNA replication (excision, incision) 4) mRNA metabolism (transcription
(MEF2C), translation, splicing), Viral replication 5) PAK-2p34 proteosome mediated degradation;
Alzheimer's disease pathway; NRIF cell death signaling 6) calcium-dependent cell adhesion; 7)
synaptic transmission (BIN1); detection of chemical stimulus; protein amino acid prenylation 8)
metal transport (Cu+2), aerobic respiration, acetyl-CoA metabolism 9) amino sugar metabolism (N-
acetylglucosamine); 10) selenoamino acid metabolism; peptidyl-arginine methylation
Aβ42 119(82) 2313 1) Copper ion homeostatsis, aerobic respiration, metal ion transport 2) Protein trafﬁcking 3)
Immunity and defense (CR1); acute inﬂammatory response (CR1, CLU); BMP-signaling
pathway; cell adhesion, cell-cell junction organization, nervous system development, plug
formation, integrin-mediated signaling (via MPK and Grb2:SOS), post-translational gene silencing.
4) ectodomain proteolysis, Notch processing, Alzheimer's disease pathway, Preselinin action in
Notch and Wnt signaling, learning or memory, apoptosis (DSG2) 5) Neuron recognition, calcium
dependent cell adhesion, axonal fasciculation 6) mRNA metabolism (transcription, translation,
splicing), inﬂuenza life cycle, and HIV elongation 7) Selenoamino acid metabolism 8) Arginine,
proline, and triacylglycerol metabolism 9) Vamp 2,7, 8 associated clathrin vesicle budding 10)
DNA packaging, chromatin assembly, and DNA packaging
sAPPα 154(109) 3084 1);erythrocyte development; EGFR signaling; steroid hormone receptor signaling; Notch receptor
processing and signaling; ectodomain proteolysis;amyloid precursor protein processing; Rho
GTPase regulation; signaling by BMP; B-cell mediated immunity; T-helper 2 cell differentiation;
Interferon-gamma production; Ras signaling in CD4+TCR pathway; cartilage development
(MEF2C); osteoclast differentiation; myeloid leukocyte differentiation (TREM2); chondrocyte
differentiation(MEF2C); regulation of transcription; positive regulation of cell proliferation
(PTK2B, SORL1) 2) heart contraction; phosphatidic acid metabolism; role of ZNF202 in
Artherosclerosis; 3) antigen presentation; caspase cascade in apoptosis 4) mRNA metabolism
(transcription, translation, splicing), viral messenger mRNA synthesis 5) visual perception; vitamin
A and retinol metabolic process; glucose homeostasis; regulation of insulin secretion 6)
Endoderm development 7) Glycosphingolipid Biosynthesis—Neolactoseries 8) protein targeting to
Golgi 9) Glycolysis and gluconeogenesis; GTP metabolism 10) unsaturated fatty acid metabolism
sAPPβ 154(102) 3608 1)Pancreas development; maturity onset diabetes of the young; cells; brain development; neuron
fate commitment; cell fate commitment; skeletal development; mesoderm development (EPHA1,
MEF2C); axis speciﬁcation;; hemopoietic progenitor cell differentiation; 2) male sex differentiation;
sex determination; response to osmotic stress 3) defense response (CR1, CLU, CD33, TREM2);
TREM 1 signaling; type I interferon production; cytokine secretion; MyD88-dependent toll-like
receptor signaling; immunoglobulin mediated immune response; B-cell mediated immunity;
leukocyte migration; adipocytokine signaling; caspase cascade in apoptosis; DNA deamination;
superoxide release 4) regulation of transcription in response to stress; porphyrin catabolism;
Calcineurin NFAT-dependent transcription in lymphocytes 5) Blood coagulation (PTK2B); Plug
formation 6) memory 7) gamma-aminobutyric acid transport 8) transcription (MEF2C);
translation; splicing; HIV infection and production (DSG2); 9) dATP/dITP metabolism 10) Golgi
to ER retrograde transport; vesicle coating (PICALM); vesicle targeting; Transport_RAB1A
regulation pathway; Caveolar-mediated Endocytosis; membrane budding (PICALM); pancreatic
juice secretion
(Continued)
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Identifying the “landscape” of APP processing: pathways that regulate
Aβ42 levels
In total, 82 unique pathways/process were identified from either Net or ABS PI scores (Fig. 1;
Table 1). Fig. 1 summarizes the main biological processes and pathways that regulate Aβ42
production. One of the most significant regulators of Aβ42 levels was the “Alzheimer's disease
pathway” (Net PI -4.66, P = 0.0014; ABS PI 7.37, P = 0.0009) as defined by the KEGG database
(Fig. 1, Table 1)[26]. This pathway contains APP itself, the γ-secretase complex, β-secretase en-
zymes (BACE1 and BACE2), as well as other enzymes known to either cleave APP or degrade
Aβ42, such as insulin degrading enzyme (IDE) and neprilysin[27]. Note that not all the genes
in the pathway have a significant Z score (e.g.>+2 or< -2), despite the fact that many of
these genes (e.g. IDE, neprilysin) are involved in either the production or degradation of Aβ42
(S6 Supplementary Information). However, since we are considering the whole pathway, as op-
posed to just individual genes, these genes are not excluded from further consideration.
Other significant gene sets that are consistent with the expected biology include the follow-
ing: “Notch receptor processing and trafficking”; “membrane protein ectodomain proteolysis”
(the general mechanism involved in processing type I transmembrane proteins such as APP);
and “Presenilin action in Notch and Wnt signalling”. Some of the most significant pathways
were those associated with gene transcription, mRNA splicing, and protein translation. These
observations are also consistent with biological expectations that: (1) knock-down of APP and
its corresponding proteolytic enzymes would reduce Aβ42 production; and (2) knock-down of
a gene in transcription/translation related processes would result in lower levels of protein pro-
duction, and hence Aβ42[20]. Such biological consistency can also be observed for other read-
outs. For example, most processes known to affect Aβ42 also affect Aβ40 (see below), which is
expected given that both these peptides are produced as a result APP proteolysis by the same
enzymatic complex (S7 Supplementary Information).
Since proteins can participate in more than one biological process/pathway, and because
there are similarities and differences in how databases define pathways, we derived a matrix
representing all vs. all overlap of these gene sets in order to identify redundancies as well as
cross-talk across Aβ42-regulatory processes (Fig. 1B). The overlap matrix was then clustered to
identify highly overlapping pathways and processes (see Materials & Methods). The clustering
procedure produced ten clusters of overlapping pathways/processes, and revealed the regulato-
ry landscape of Aβ42 (Fig. 1B, Table 1). Table 1 provides a description of the main themes for
each cluster. The landscape also illustrates the cross-talk across distinct cellular processes
where, as expected, sets such as “neuron recognition” and “axonal fasciculation” overlap with
Table 1. (Continued)




Summary of Key Pathways/Process (Table 1)
Total 372(208) 6347
Pathway/processes identiﬁed as regulating each readout are listed (see supplementary information for full list) and organized based on cluster
membership. Each cluster corresponds to pathway/processes sets that have a high degree of overlap (i.e. share common genes) (see Fig. 1B). Most of
the pathway/processes listed here are consistent with factors known to play a role in the pathogenesis of Alzheimer’s disease (see supplementary
information)[25]. Number of gene sets (pathways/processes) identiﬁed as signiﬁcant for each readout at P < 0.01. * The number in parentheses indicates
the number of unique gene sets after merging identical gene sets based on size and composition; some gene sets are identical and only differ in how they
are named (see S12 Supplementary Information). In bold are pathway/process sets that contain at least one gene (in parentheses) found to be signiﬁcant
in AD GWAS studies [21,22,25]. In italics correspond to pathways/processes directly associated with APP processing.
doi:10.1371/journal.pone.0115369.t001
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Fig 1. Identification of pathways that regulate APP processing (Aβ42). A. By combining the P-value and
PI score, we identified pathways/processes that, when knocked down, significantly affect the readout in
question. Depicted here are the results for Aβ42 readout. Each circle represents a process/pathway set and
the size of the circle corresponds to the number of genes, measured in the screen, that comprise each
pathway. Colors correspond to the database from which the pathway/process set was derived. Y-axis
represents the likelihood of a pathway of a given size to have the corresponding net or absolute PI score by
chance. Black dotted line corresponds to p-value = 0.01 or -log10(p-value) = 2. One of the most significant
sets was the AD pathway as defined by KEGG (red arrow). This pathway contains γ-secretase, β secretase,
and other enzymes known to either cleave APP or degrade Aβ42. B. Clustering of candidate pathways/
processes based on gene overlap. The overlap between two pathways/processes is determined by the ratio
of the overlap of the smaller with the larger set to the size of the smaller set (see materials and methods).
Clusters (black boxes) of highly overlapping pathways/processes were identified using hierarchical
Elucidating the Regulatory Landscape of APP Processing
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“memory”, but also overlap with “calcium-dependent cell adhesion” and “immunity and de-
fence” pathways. Another example is the overlap between “cell junction and maintenance”
with processes such as “mRNA editing” and “gene transcription”. Cluster 4 contains several
processes known to regulate APP processing (Fig. 1B). Several of these pathways and processes
have been implicated in AD pathogenesis and cover most strategies under consideration for
the treatment and prevention of AD (Fig. 1B) as well as several candidate risk factors identified
in GWAS studies (Table 1; S8 Supplementary Information)[1,3,7,9,24].
Other pathways and processes were also identified. Examples include "Integrin-mediated
signalling", "neuron recognition", "BMP signalling pathway", "Arginine and proline metabo-
lism", and "Lectin pathway of complement activation" (see S4 and S5 Supplementary Informa-
tion). Links between some of these pathways/processes and AD and amyloid have been
reported previously [28–36]. However the specific molecular mechanisms of how these pro-
cesses are linked to AD have not been fully determined. Our results suggest that these processes
regulate Aβ42 biology.
Differential impact of pathways/processes on biological endpoints
APP processing is mediated by different enzymes and therefore, it is plausible that regulation of
these enzymes, and subsequently APP processing, could result from activation/de-activation of
different pathways. We clustered the pathways/processes using Net PI scores in order to identify
differential and similar patterns of regulation. Fig. 2 illustrates how some pathways differentially
regulate viability and APP proteolytic products (see S9 Supplementary Information).
Differential regulation of Aβ42 vs. Aβ40 peptides. Selective lowering of Aβ42 peptides
over Aβ40 can be achieved by modulating the γ-secretase complex pharmacologically or via
transient protein—protein interactions without affecting cleavage of the Notch protein
[4,9,37,38]. Therefore, further understanding of biological mechanisms that selectively regulate
the production of Aβ42 over Aβ40 is of interest.
Although most processes that were significant for Aβ42 production were also significant for
Aβ40, some pathways were significant for one and not for the other (Fig. 3), such as "synaptic
transmission" and "Vamp 2, 7, and 8 associated clathrin derived vesicle budding". Although
synaptic activity affects levels of both Aβ40 and Aβ42, knock-downs of some of the genes in
this biological process have a significantly larger effect on Aβ40 levels than on Aβ42[39]. Inter-
estingly, knock-down of Vamp8 has been shown to reduce Aβ42, but not Aβ40 levels, suggest-
ing potential differences in membrane targeting and/or fusion of these peptides[40].
Differential regulation of sAPPα vs. sAPPβ production. Pathways that differentially
regulate sAPPα and sAPPβ were also identified. Contrary to the production of Aβ40 and Aβ42,
which are regulated by the same enzymatic complex, the production of sAPPα and sAPPβ is
regulated by distinct enzymes such as the metalloproteinases TACE/ADAM10, ADAM17, and
MDC-9, and the aspartyl protease BACE1, respectively[1,41]. Furthermore, production of
sAPPα is mainly mediated extracellularly, and is usually associated with processes that are
thought to be beneficial to the cell such as neuronal transmission[1,39,41]. Conversely, sAPPβ
clustering. Cluster 4 contains the AD pathway. This type of representation also allows for the identification of
interplay across the different pathways/processes. For example, the red-dashed squares indicate overlap
between sets in Cluster 3 (inflammation and cell adhesion) with genes in Cluster 6 (mRNA processing,
translation, and transcription). The table captures each cluster which consists of pathways/processes that
share similar overlapping patterns. Several of these pathways/processes have been implicated in modulating
γ-secretase activity, have been implicated in AD pathogenesis, and/or are under consideration as strategies
for the treatment and prevention of AD [1,3,7,24].
doi:10.1371/journal.pone.0115369.g001
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Fig 2. Differential effects of pathways on different readouts.Not all pathways, if knocked down by siRNA,
affect biological endpoints in the samemanner. A. The dendrogram on the left represents hierarchical
clustering of pathways across different readouts using their Net PI score. Each row corresponds to a
pathway. Blue: negative PI score (readout decreased). Red: positive PI score (readout increased). B.
Individual pathway/process profiles across the readouts for each cluster. This representation allows one to
identify pathways/processes that may have favourable profiles (lower net levels of amyloidogenic peptides),
such as Cluster 2 and Cluster 6, and those with undesirable profiles (greater net levels of amyloidogenic
peptides), such as Cluster 10. Cluster 2 and Cluster 6 show reduction in the amyloidogenic peptides Aβ40,
Aβ42, and sAPPβ, with increases in sAPPα (β-secretase-inhibition profile) and no net decrease in viability.
Conversely, Cluster 10 pathways have strong net decreases in viability and net increases in amyloidogenic
peptides, and hence could be potentially considered pathological.
doi:10.1371/journal.pone.0115369.g002
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Fig 3. Pathways/processes that differentially regulate Aβ42 vs. Aβ40 production. A. Scatter plot of -log
(-P-values) for Net PI scores of pathways/processes for Aβ42 against that for Aβ40. Each circle represents a
pathway/process. The size of the circle corresponds to the number of genes in the set. The color corresponds
to the database source from which the pathway/process was derived. As expected, most pathways and
processes that regulate Aβ40 also regulate Aβ42 production. However, there are some “modulator” pathways
that are significant for one readout but not the other. Red square: Aβ42-regulating pathways. Blue square:
Aβ40-specific pathways.
doi:10.1371/journal.pone.0115369.g003
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is produced intracellularly as BACE1 is mainly located in the late Golgi/trans-Golgi network
and endosomes[41]. Consistent with the cellular location of BACE1, pathways/processes such
as “Golgi-to-ER retrograde transport (REACTOME pathways)”, “retrograde vesicle-mediated
transport, Golgi to ER (GO Biological Process)”, and “caveolar-mediated endocytosis (Ingenui-
ty Pathways)” were found to be significant regulators of sAPPα but not of sAPPβ, whose pro-
duction is mainly limited to the cell surface (Table 1; see S10 Supplementary Information).
In addition to cell-compartmental differences, pathways/processes such as “maturity-onset di-
abetes of the young (KEGG pathways)”, “adipocytokine signalling pathway (KEGG pathways)”,
and processes involved in pancreas biology and development were found to be significant for the
production of sAPPα but not for sAPPβ (see S10 Supplementary Information). These observa-
tions are consistent with the emerging role of insulin resistance and deficiency in AD[42].
Pathway-based analysis facilitates identification of mechanistic link
between AD and diabetes
So far, the detailed underlying mechanism by which diabetes and AD can be linked is un-
known[1]. In order to understand how regulation of this pathway affects the production of
sAPPβ we generated two different views of the “Maturity onset diabetes of the young” pathway,
one that demonstrated how individual proteins in this pathway regulate APP processing (Figs.
4A-D) and the other that consisted of proteins from this pathway as well as the “AD pathway”
(Figs. 4A-D), with the aim of determining whether proteins in the diabetes pathway would in-
teract with/regulate proteins that have been implicated in AD.
Maturity onset of diabetes of the young, or MODY, is a monogenic form of diabetes with
onset at adolescence and early adulthood. Mutations in genes in this pathway limit the ability of
the pancreas to produce insulin[43]. Knock-downs of proteins involved in “Maturity onset dia-
betes of the young”, or MODY, have different effects on APP proteolytic products. For example,
knock-down of NKX2–2, which is a homeobox transcription factor, results in a significant de-
crease of sAPPβ (Z = –12.3) but increases sAPPα (Z = 2.4). Hence, the mechanism by which
this pathway would favour the production of sAPPβ over sAPPαmay be mediated by this tran-
scription factor, or potentially via other transcription factors such as HNF4A (Fig. 4D).
Discussion
In this report we demonstrate that pathway-based analysis of genome-wide siRNA screens can
be leveraged to identify key regulatory processes of different biological endpoints; in this case
proteolytic processing of APP. This was achieved despite the known limitations of large-scale
siRNA screens, suggesting that leveraging our knowledge of biological pathways/processes can
improve our ability to interpret and leverage this technology.
Most processes/pathways identified in this study have been implicated in AD and in APP bi-
ology as well as in ageing and neuronal vulnerability [1,9,24,44] (S8 Supplementary Informa-
tion). Many of the risk factors (CLU, BIN1, PICALM, CR1, CD33, EPHA1, TREM2) recently
identified in several GWA studies are members of processes/pathways found to be significant
for at least one of the readouts including 5 candidate genes (PTK2B, SORL1, DSG2, INPP5D,
MEF2C) from newly identified loci based on meta-analysis (see Table 1)[21,22,25,45]. In other
words, almost 50% of the risk factors identified in GWAS studies are members of the processes
identified in our work. For example, Clusterin (CLU or APOJ) and CR1 (complement compo-
nent 3b/4b) are members of the “acute inflammatory response” biological process, which has
been found to impact Aβ42 production significantly (Fig. 2, Table 1). Wakabayashi et al. dem-
onstrated how proteins involved in vesicle trafficking, adhesion, and integrin signalling affect
the levels of Aβ40 and Aβ42 via interactions with the γ-secretase complex[40]. Such
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Fig 4. “Maturity onset diabetes of the young” pathway (KEGG) [26]. This pathway was found to be a
significant regulator of sAPPβ. Proteins/genes are coloured based on their corresponding Z* values for
sAPPα (A), and sAPPβ (B). Genes do not behave equally across the different readouts. For example, knock-
down of NKX2–2 (black circle), which is a homeobox transcription factor, results in a significant decrease of
sAPPβ (Z* = –12.3) but increases sAPPα (Z* = 2.4). Hence, the mechanism by which this pathway would
favour the production of sAPPβ over sAPPα could potentially be mediated by this transcription factor. C.
“Maturity onset diabetes of the young (MODY) (KEGG)” and "Alzheimer's disease" pathways (KEGG
database). The network illustrates how proteins from these two pathways interact with/regulate each other. D.
Two potential mechanisms by which sAPPβ levels can be lowered. One hypothetical mechanism could be via
NKX2–2 regulation of APP processing via an insulin-mediated pathway. Knock-down of NKX2–2 would result
in increased insulin levels leading to inhibition of caspase 3 activation and hence decreased cleavage of APP
by caspase 3 at the BACE1 cleavage site[69–71]. Increased insulin levels have been associated with
decreases of intracellular accumulation of Aβ levels, and caspase 3 has been shown to regulate APP
processing via BACE1-related mechanisms [71–73]. Knock-down of caspase 3 in this study reduces sAPPβ
levels. Although the insulin gene was not included in the screen, the knock-downs of NKX-2 and caspase 3
are consistent with known biology (i.e. reduction in levels of sAPPβ. An alternative hypothesis could be via
HNF4A, a transcription factor previously characterized as binding to the BACE promoter [74]. Genes/proteins
in the network are coloured by their corresponding sAPPβ Z* values.
doi:10.1371/journal.pone.0115369.g004
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observations are consistent with our identification of “Vamp 2,7, and 8 mediated vesicle traf-
ficking”, "integrin-signalling pathway" and “cell adhesion pathways” as regulators of Aβ42 pro-
duction[40] (Fig. 2C, Table 1 clusters 3 and 9). The identification of “BMP signalling pathway”
as a regulator of Aβ42 is also consistent with observations that blocking TGF-β–Smad2/3 im-
mune signalling attenuates brain parenchymal and cerebrovascular amyloid deposits in
Tg2576 mice, an animal model of AD that overproduces Aβ42[46]. Similarly, processes shown
to regulate γ-secretase activity, such as synaptic transmission, inflammation, and cholesterol
metabolism (triacylglycerol metabolism), were identified [1,9] (Table 1). Recently DKK1 and
Wnt have been implicated in Clusterin regulation of Aβ toxicity, both of which are members of
the “Presenilin action in Notch and Wnt signalling” found here to be significant regulator of
Aβ42 (see Table 1)[47]. These observations provide additional supporting evidence for the role
of these processes in APP biology.
In addition to identifying pathways/processes that are relevant for APP biology, we also iden-
tified pathways that differentially regulate APP processing. Although common pathways/pro-
cesses were found to regulate Aβ40 and Aβ42, in some cases there was a bias of processes
towards one peptide over the other, suggesting that some of the processes may modulate the γ-
secretase complex and, thus, providing novel mechanisms of selective lowering of Aβ42. Differ-
ences in pathways were even more pronounced between sAPPα and sAPPβ as expected, given
the different enzymes responsible for their production and differences in subcellular localization
of where these peptides are produced [9]. Of interest was the identification of processes/pathways
related to diabetes (such as the MODY pathway) as significant for the production of sAPPβ but
not for sAPPα, consistent with the growing role of metabolic disorders in AD[1,48–52].
The MODY pathway contains several transcription factors that are critical not only for the
proper development of pancreatic islet cells, but also for neuronal development[53]. There is a
clear difference between the effects of knocking down NKX2.2 between sAPPα and sAPPβ sug-
gesting a role of this transcription factor in differential regulation of APP processing. While the
precise mechanism of how the MODY pathway regulates APP processing remains to be deter-
mined, by leveraging protein-protein interaction networks in conjunction with siRNA data, we
can propose plausible hypotheses; this pathway may regulate APP biology either via NKX2.2,
insulin, and caspase mediated mechanism or via HNF4A regulation of BACE1 (see Fig. 4 for
more details). This underscores the power of pathway/process-based analysis of siRNA screens,
where a biological context can be leveraged not only for the interpretation of a screen, but also
in subsequent validation experiments. For example, animal models of NKX2.2 are available
and so are activators and inhibitors of GCK, a glucokinase that is a member of the MODY
pathway (Fig. 4)[54–56]. In other words, pathway scoring provides a top down approach of
identifying the pathway/process of interest, followed by detailed drill down on potential mech-
anisms, as opposed to trying to build the rationale based one gene at a time.
Selecting genes of interest based on extreme values poses a few challenges. First, it is well
documented that off-target effects plague the interpretation of siRNA screens, where the effect
of an siRNA probe on the biological endpoint is a result of down-regulation of the off-targets
as opposed to the initially intended target [57]. Many notable efforts have been made in devel-
oping methods to address these issues [58–61]. Secondly, even in the event that off-target ef-
fects were not an issue, siRNA probes are not equally potent; genes may have a small effect on
the endpoint due to compensatory mechanisms, and protein stability is not uniform across
siRNA targets. For these reasons, we focused on prioritizing pathways/processes as opposed to
individual genes. We assume that the off-target effects for each siRNA probe/gene are indepen-
dent and that there is a very small likelihood of siRNA probes, targeting different genes in the
same pathway, to have the same off-target effects that would contribute to the regulation of the
same phenotype (e.g., lowering levels of Aβ42). Hence, the permutation analysis can test
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whether the relationship of genes in a pathway/process in aggregate should have a larger effect
than when no relationship is present; that is, they do not work in concert in the same pathway
or process. In fact, not all gene sets that contained genes with extreme values were significant,
suggesting that context is important in determining significance (Fig. 5). Furthermore, we were
able to rescue false negatives by focusing on the pathway level (see S6 Supplementary
Information).
The agreement between our results, human genetic studies, and the literature supports the
idea that a pathway-based analysis of whole-genome siRNA screens can be used to map the
regulatory landscape of different biological endpoints. Pathways/processes in such a landscape
can be categorized as follows: (1) direct mechanisms (e.g. γ-secretase complex); (2) related but
not direct regulatory mechanisms (e.g. other signalling pathways that regulate APP cleaving
enzymes, feedback mechanisms, vesicle trafficking of soluble APP proteolytic products, and
protein degradation); and (3) general cellular mechanisms that are likely to impact any readout
(e.g. protein translation, gene transcription, and mRNA splicing. Although these mechanisms
may seem distinct, proteins can participate in different processes in the cell. To this end we de-
rived a relationship view of their cross-talk facilitating the interpretation of how these processes
are inter-related (see S11 Supplementary Information).
We hope that the pathways/processes identified herein, and our derivation of their relation-
ship to one another, provides a comprehensive systems biology view of APP biology that will
serve as a useful resource for the AD community to further dissect the role of APP physiology,
the implications of other pathophysiologies in AD, and to help identify novel Aβ
lowering strategies.
Materials and Methods
APP siRNA screen and data processing
The siRNA screen used in this study is described in Majercak et al.[20]. Briefly, the screen uses
HEK-293 cells, a kidney derived cell line, stably expressing a mutant form of APP that contains
a four amino-acid modification (NFEV) designed to enhance cleavage by the BACE1 enzyme
(S7 Supplementary Information)[20]. These cells were transfected with different siRNA pools
(n = 3 per gene). Conditioned media from these cells were then removed after 48 hrs following
incubation with siRNA pools. Aliquots were used to detect different APP proteolytic products:
Aβ40, Aβ42, sAPPα, and sAPPβ. In addition, cell viability was determined by incubating cells
for 2 hrs with Alamar blue.
Raw intensities from the original screen were re-processed in order to achieve the following:
(1) to normalize all peptide-related values (Aβ40, Aβ42, sAPPα, and sAPPβ) to viability in
order to account for differences in peptide levels that may result from differences in cell num-
ber; and (2) to account for plate-edge effects that were observed in the original screen. The
original screen[20] reported values as percent activity, which is defined as the percent effect of
knocking down a gene relative to a reference control. We introduced a more effective measure
(denoted Z) to represent the values for each siRNA pool. Let Yi be the measured activity for a
given well (log intensity), ~YN the median value of all samples, N, in the plate, andMADN the
median absolute deviation[12] of measured values. The Z score is defined as





The original screen used 15,200 siRNA pools, some of which contained siRNA probes for
which a corresponding gene could not be assigned, and/or had multiple replicates for the same
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Fig 5. Pathway/process context matters.Not all pathways/processes that contain genes with extreme
values are significant suggesting that the approach may be resistant to to outliers. For example, ITGB3 and
APP are clear outliers with Z* scores of 7.18 and -7.1, respectively but not all of their corresponding
pathways/processes were found to be significant regulators of Aβ42. Each circle corresponds to pathway/
process and the size corresponds to the number of genes in that pathway/process. Y-axis represents the
likelihood of a pathway of a given size to have the corresponding net or absolute PI score by chance. Black
dotted line corresponds to p-value = 0.01 or -log10(p-value) = 2 and the x-axis corresponds to the either Net or
ABS PI score based on the Aβ42 readout.
doi:10.1371/journal.pone.0115369.g005
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siRNA pool; this pool was being used as an internal control. We removed all probes that could
not be assigned to a gene. Furthermore, for every gene with multiple siRNA pools, the averaged
Z value was used. In total, 14,603 siRNA pools, representing 13,537 unique genes, were con-
sidered for analysis.
Pathway/process data-set collection and representation
We compiled several gene sets representing pathways and biological processes from the fol-
lowing commercial and public databases (S2 Supplementary Information): NCI Nature Path-
ways[62], KEGG[26], Ingenuity (Ingenuity Systems, www.ingenuity.com), Reactome [63],
GeneGo Metabase (www.genego.com), Panther Biological Processes[64], and Gene Ontology
Biological Process[65]. These sources represent a list of human-curated pathways and biologi-
cal processes. Pathway sets from Reactome and NCI Nature Pathways were retrieved using
the cPATH [66] tool from the Pathway Commons website; only pathways that contained at
least one gene used in the siRNA screen were considered. For each given pathway/process set,
only those genes used in the siRNA screen were retained for the analysis. As a result the size of
the processed gene set corresponds to the intersection of the genes in the original set and
those monitored in the screen. Sets containing<3 genes and>1,000 genes were also excluded.
The upper bound is an arbitrary cut-off indicating that sets of>1,000 genes are unlikely to
yield meaningful biological interpretation. In total, 6,154 gene sets representing pathways
and/or biological processes were used, with 95% (12,859) of all genes in the screens being as-
signed to at least one set. All the gene sets used in the screen can be found in the S2 Supple-
mentary Information as well as in the TargetMine system (http://targetmine.nibio.go.jp/
applandscape/) [67].
Pathway impact (PI) scores and simulation P-value calculations














where n is the number of genes in a pathway/process set, and Zi is the Z score for each indi-
vidual gene in that pathway/process set. The ABS PI score is calculated to mitigate against the
scenario in which small PI scores could result from equal but opposing effects of genes in a
given pathway/process.
The probability P of obtaining by chance a PI score equal to or greater than the observed
one for a given set of size n was calculated as follows: the Net or Absolute PI score was comput-
ed for 10,000 random selection of n genes from the screen in order to derive the null distribu-
tion for each set size. Then, the probability P was determined by the proportion of random PI
scores that were equal to or more extreme than the observed PI score. Pathway/process sets
were considered significant if P 0.01 for either the Net or ABS PI scores for each readout, re-
spectively. Volcano plots for the results were created using Spotfire Decision Site 9.1 (http://
spotifire.tibco.com); PI scores for Net or ABS values are reflected in the x-axis and P-values are
represented on the y-axis as -log10(P-value) and hence the cut-off is -log10 0.01 = 2.
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Derivation of the overlap matrix
In order to identify the extent of overlap between different gene sets, we calculated the overlap
coefficient Oc between two sets i and j as follows:
Ocði; jÞ ¼ jSi \ Sij=½minðjSij; jSjjÞ
where jSi \ Sij is the number of genes shared by the two sets Si and Sj, and minðjSij; jSjjÞ is the
smaller size of the two sets considered[68]. Oc was then used to create a symmetric overlap ma-
trix of all-versus-all set comparisons. An overlap of 1 means either: (1) the sets are identical in
size and composition; or (2) the smaller set is a true subset of the larger set; conversely, an over-
lap of 0 means that the sets share no genes. The overlap was calculated based on the composi-
tion of gene sets (pathways/processes) with respect to the screen. Hence, the degree of overlap
between two gene sets in this study may differ from the overlap of these sets when considering
the complete membership for each set.
Identification of highly overlapping pathway/process clusters
The overlap coefficient matrix Oc was re-ordered to identify clusters that represented related
pathways/processes. Briefly, rows and columns of the matrix were re-ordered by first calculat-
ing a distance matrix based on cosine-correlation followed by average linkage clustering [68].
A matrix view was generated using the values from the Ocmatrix and ordering from the clus-
tering run. The generation of the cosine-correlation distance matrix and average linkage clus-
tering were performed using the pdist and linkage functions, respectively, in Statistic Tool
Box of Matlab 7.4.0 (www.mathworks.com). The matrix was plotted using Spotfire Decision
Site 9.1 (www.tibco.com).
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